Endotis takes in £4.5M in three public awards

Development awards

Glycobiology specialist Endotis Pharma SA has been awarded three major public finance awards totaling €4.5 million from the French government innovation body, OSEO, and the bioclusters Paris Medicen and Alsace Bio Valley. 

The company, based in Biocitech Park, Romainville, near Paris is developing of small molecule glyco drugs as treatments for thrombosis, cancer and other indications. Endotis was awarded €2.2 million from OSEO for the clinical development of EP42675/EP217609, a dual-acting antithrombotic. Phase II clinical studies are scheduled to start in early 2009 with EP42675 in Acute Coronary Syndrome.

A second project, DOSCA (Development of OligoSaccharide in CAncer) has won a €1.1 million grant from the Paris Medicen cluster to support development of the company’s oligosaccharide-based oncology platform. Endotis says compounds based on this platform will act on multiple targets to inhibit solid tumor growth and metastasis.

In the third project, HORUS (Development of Oral antithrombotics), Endotis has been awarded €1.1 million from the Alsace BioValley and Paris Medicen clusters. This grant will support the development of an oral antithrombotic based on Endotis’s oligosaccharide expertise and the softgel encapsulation technology developed by Catalent Pharma Solutions, working with the UMR311 team of Inserm at the Université Louis Pasteur.

“The award of these grants and public finance reflects the quality of the R&D programmes developed by Endotis and its partners,” said Charles Woler, Endotis Pharma’s Chairman and CEO. “This financing will enable us to expand our oncology drug discovery programme, to develop our oral small-glyco drugs platform, and to move forward with our EP42675/EP217609 injectable antithrombotics programme.”